| Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis RL Levine, M Wadleigh, J Cools, BL Ebert, G Wernig, BJP Huntly, ... Cancer cell 7 (4), 387-397, 2005 | 3921 | 2005 |
| A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis S Verstovsek, RA Mesa, J Gotlib, RS Levy, V Gupta, JF DiPersio, ... New England Journal of Medicine 366 (9), 799-807, 2012 | 2353 | 2012 |
| Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study NM Kuderer, TK Choueiri, DP Shah, Y Shyr, SM Rubinstein, DR Rivera, ... The Lancet 395 (10241), 1907-1918, 2020 | 1944 | 2020 |
| New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment F Cervantes, B Dupriez, A Pereira, F Passamonti, JT Reilly, E Morra, ... Blood, The Journal of the American Society of Hematology 113 (13), 2895-2901, 2009 | 1571 | 2009 |
| Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis S Verstovsek, H Kantarjian, RA Mesa, AD Pardanani, J Cortes-Franco, ... New England Journal of Medicine 363 (12), 1117-1127, 2010 | 1380 | 2010 |
| MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients AD Pardanani, RL Levine, T Lasho, Y Pikman, RA Mesa, M Wadleigh, ... Blood 108 (10), 3472-3476, 2006 | 1361 | 2006 |
| Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis … A Tefferi, J Thiele, A Orazi, HM Kvasnicka, T Barbui, CA Hanson, G Barosi, ... Blood, The Journal of the American Society of Hematology 110 (4), 1092-1097, 2007 | 1210 | 2007 |
| Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet T Barbui, G Barosi, G Birgegard, F Cervantes, G Finazzi, M Griesshammer, ... Journal of clinical oncology 29 (6), 761-770, 2011 | 1087 | 2011 |
| Ruxolitinib versus standard therapy for the treatment of polycythemia vera AM Vannucchi, JJ Kiladjian, M Griesshammer, T Masszi, S Durrant, ... New England Journal of Medicine 372 (5), 426-435, 2015 | 1052 | 2015 |
| Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet T Barbui, A Tefferi, AM Vannucchi, F Passamonti, RT Silver, R Hoffman, ... Leukemia 32 (5), 1057-1069, 2018 | 615 | 2018 |
| Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for … G Barosi, RA Mesa, J Thiele, F Cervantes, PJ Campbell, S Verstovsek, ... Leukemia 22 (2), 437-438, 2008 | 581 | 2008 |
| Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among … RM Emanuel, AC Dueck, HL Geyer, JJ Kiladjian, S Slot, S Zweegman, ... Journal of clinical oncology 30 (33), 4098-4103, 2012 | 553 | 2012 |
| TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis A Tefferi, A Pardanani, KH Lim, O Abdel-Wahab, TL Lasho, J Patel, ... Leukemia 23 (5), 905-911, 2009 | 546 | 2009 |
| The burden of fatigue and quality of life in myeloproliferative disorders (MPDs) An international internet‐based survey of 1179 MPD patients RA Mesa, J Niblack, M Wadleigh, S Verstovsek, J Camoriano, S Barnes, ... Cancer 109 (1), 68-76, 2007 | 514 | 2007 |
| Population‐based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976–1995 RA Mesa, MN Silverstein, SJ Jacobsen, PC Wollan, A Tefferi American journal of hematology 61 (1), 10-15, 1999 | 509 | 1999 |
| Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial A Pardanani, C Harrison, JE Cortes, F Cervantes, RA Mesa, D Milligan, ... JAMA oncology 1 (5), 643-651, 2015 | 489 | 2015 |
| Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases RA Mesa, CY Li, RP Ketterling, GS Schroeder, RA Knudson, A Tefferi Blood 105 (3), 973-977, 2005 | 476 | 2005 |
| The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients R Scherber, AC Dueck, P Johansson, T Barbui, G Barosi, AM Vannucchi, ... Blood, The Journal of the American Society of Hematology 118 (2), 401-408, 2011 | 429 | 2011 |
| Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial S Verstovsek, RA Mesa, J Gotlib, V Gupta, JF DiPersio, JV Catalano, ... Journal of hematology & oncology 10, 1-14, 2017 | 416 | 2017 |
| Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis SV Rajkumar, RA Mesa, R Fonseca, G Schroeder, MF Plevak, ... Clinical cancer research 8 (7), 2210-2216, 2002 | 410 | 2002 |
